CD80-CAP

a synthetic CD80-binding agent; mediates protection against colitis by inducing Th2 skewing of the cytokine response

Also Known As:

CD80 - competitive antagonist peptide; CD80 blocking peptide; Gln-Cys-Pro-Gly-Met-Pro; QCPGMP

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

1.	Srinivasan, Mythily: 2 articles (12/2009 - 04/2008)
2.	Summerlin, Don-Jon: 1 article (12/2009)
3.	Eri, Rajaraman: 1 article (04/2008)
4.	Kodumudi, Krithika N: 1 article (04/2008)
5.	Summerlin, Don John: 1 article (04/2008)

1.	Colitis 12/01/2009 - "In conclusion, CD80-CAP administration ameliorated TNBS colitis by reducing the inflammatory cell infiltration and modulating the CEC response potentially restoring mucosal tolerance." 12/01/2009 - "Here we investigated the effect of the CD80-CAP on the CEC responses in experimental colitis. " 04/01/2008 - "The CD80 blocking peptide appeared to mediate protection against colitis by inducing Th2 skewing of the cytokine response." 12/01/2009 - "Furthermore, the CD80-CAP treatment suppressed Th1 cytokines and enhanced Th2 responses by the CEC in colitis mice. " 12/01/2009 - "Administration of the CD80-CAP decreased microscopic inflammation and restored the expression of TLR-2, 3, 4 and 5 mRNA in the CEC of colitis mice to physiological levels. "
2.	Inflammation (Inflammations) 12/01/2009 - "Administration of the CD80-CAP decreased microscopic inflammation and restored the expression of TLR-2, 3, 4 and 5 mRNA in the CEC of colitis mice to physiological levels. " 04/01/2008 - "Significantly, CD80-CAP (competitive antagonist peptide) treatment suppressed established inflammation in TNBS-induced colitis, a model for Th1-mediated Crohn's disease. "
3.	Crohn Disease (Crohn's Disease) 04/01/2008 - "Significantly, CD80-CAP (competitive antagonist peptide) treatment suppressed established inflammation in TNBS-induced colitis, a model for Th1-mediated Crohn's disease. "